Discover
ITRM
Iterum Therapeutics PLC
0.03
30 x 0.00
1 x 0.04
bid
ask
+
0.00
0.00%
16 @ 04:00 PM
0.03 +0.00 (5.00%)
| Ytd | -91.04% | |
| 1y | -96.91% |
0.03
day range
0.05
0.81
52 week range
3.02
| Open | 0.04 | Prev Close | 0.03 | Low | 0.03 | High | 0.05 | Mkt Cap | 48.98M |
| Vol | 49.30M | Avg Vol | 2.88M | EPS | -1.76 | P/E | N/A | Forward P/E | -2.70 |
| Beta | 2.25 | Short Ratio | 0.46 | Inst. Own | 8.99% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-15 | 50-d Avg | 1.63 | 200-d Avg | 1.40 | 1yr Est | 7.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | -0.23 | -0.3 | -0.07 | -30.43% |
| 2024-08-14 | 2024-06 | -0.52 | -0.3 | 0.22 | 42.31% |
| 2024-08-14 | 2024-06 | -0.52 | N/A | N/A | N/A |
| 2024-05-13 | 2024-03 | -0.57 | -0.46 | 0.11 | 19.30% |
| 2024-05-13 | 2024-03 | -0.57 | N/A | N/A | N/A |
| 2024-03-28 | 2023-12 | -1.02 | -0.94 | 0.08 | 7.84% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-08-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-06-21 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-31 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-04-30 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-04-01 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-06-14 | CHIN MARK | Director | 18.31K | Conversion of Exercise of derivative security |
| 2024-08-05 | DUNNE MICHAEL W | Director | 220.00K | Conversion of Exercise of derivative security |
| 2024-08-05 | FISHMAN COREY N | Chief Executive Officer | 137.06K | Conversion of Exercise of derivative security |
| 2023-06-14 | HECHT BETH P | Director | 18.84K | Conversion of Exercise of derivative security |
| 2024-08-05 | HUNT RONALD M | Director | 0.00 | Conversion of Exercise of derivative security |
| 2023-03-09 | MATTHEWS JUDITH M | Chief Financial Officer | 8.14K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Armistice Capital, LLC | 1.34M | 2.39M | 4.87% |
| 2024-09-29 | New Leaf Venture Partners, L.L.C. | 345.02K | 614.14K | 1.25% |
| 2024-09-29 | Apollon Financial, LLC | 224.75K | 400.05K | 0.82% |
| 2024-09-29 | Alpine Global Management, LLC | 64.83K | 115.40K | 0.24% |
| 2024-09-29 | Xtx Topco Ltd | 33.04K | 58.81K | 0.12% |
| 2024-09-29 | Two Sigma Securities, LLC | 14.95K | 26.61K | 0.05% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 12.37K | 22.02K | 0.04% |
Split
| Split | Date |
|---|---|
| 1 : 15 | 2022-08-18 |